A new technique that complements sentinel lymph node biopsy: lymph node dissection under the intercostobrachial nerves in early-stage breast cancer.

Abstract:

BACKGROUND:Arm lymphedema is a common complication after axillary lymph node dissection (ALND), and there is no effective treatment. The clinical significance of sentinel lymph node biopsy (SLNB) is to avoid the risk of arm lymphedema caused by ALND in cases in which the nodes are negative for cancer cells. In developed countries, sentinel lymph node (SLN) localization methods by using combined dye and radioactive tracer techniques predict the lymph node status in early-stage breast cancer with comparable success rates, accuracy, and false-negative rates. In fact, most researchers agree that the combined technique has significantly higher accuracy than marking the sentinel nodes with dye alone. In China, the radioactive tracer technique is mostly used in research but not in clinical surgery, where it is not permitted. The necessity of intercostobrachial nerves (ICBN) preservation is now accepted by the surgeons and has become the standard procedure in such dissections, which reduces postoperative skin numbness and loss of feeling in the upper arm. METHODS:In our study, the data of 177 patients were analyzed to identify the feasibility of such an assignment and potential clinical significance of ICBN in dividing the axillary space. RESULTS:We found that the mean value for the number of nodes under the ICBN was enough for accession, the lymphedema caused by axillary lymph nodes dissection under the intercostobrachial nerves (PALND) was similar with SLNB and lower than ALND, and the PALND can make up for SLNB in false negative (SLNs are negative, while non-SLNs are positive). CONCLUSION:ALND under the ICBN could be considered a procedure complementary to SLNB in early-stage breast cancer in China, where the radioactive tracer technique is not widely applied.

journal_name

Clin Breast Cancer

journal_title

Clinical breast cancer

authors

Li J,Jia S,Zhang W,Zhang Y,Qiu F,Xue J,Gu X

doi

10.1016/j.clbc.2012.10.005

subject

Has Abstract

pub_date

2013-06-01 00:00:00

pages

212-8

issue

3

eissn

1526-8209

issn

1938-0666

pii

S1526-8209(12)00298-4

journal_volume

13

pub_type

杂志文章
  • Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?

    abstract:AIM:Our study was to investigate the heterogeneity of estrogen receptor (ER) expression among tumor sites by using fluorine-18 ((18)F) fluoroestradiol (FES) positron-emission tomography-computed tomography (PET-CT) imaging. METHODS:Thirty-two breast cancer patients underwent both (18)F-FES and (18)F fluorodeoxyglucose...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2013.02.012

    authors: Yang Z,Sun Y,Zhang Y,Xue J,Wang M,Shi W,Zhu B,Hu S,Yao Z,Pan H,Zhang Y

    更新日期:2013-10-01 00:00:00

  • The evolving role of aromatase inhibitors in adjuvant breast cancer therapy.

    abstract::The development of third-generation aromatase inhibitors (AIs) has brought about a major change in the therapeutic approach to patients with hormone-sensitive breast cancer. In randomized clinical trials, each of the third-generation AIs has demonstrated efficacy in the adjuvant treatment of postmenopausal women with ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CBC.2005.n.022

    authors: Henderson IC,Piccart-Gebhart MJ

    更新日期:2005-08-01 00:00:00

  • Role of Magnetic Resonance Imaging in Detection of Pathologic Complete Remission in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: A Meta-analysis.

    abstract::Pathologic complete remission after neoadjuvant chemotherapy has a role in guiding the management of breast cancer. The present meta-analysis examined the accuracy of contrast-enhanced magnetic resonance imaging (CE-MRI) and diffusion-weighted magnetic resonance imaging (DW-MRI) in detecting the response to neoadjuvan...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clbc.2016.12.010

    authors: Gu YL,Pan SM,Ren J,Yang ZX,Jiang GQ

    更新日期:2017-07-01 00:00:00

  • Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials.

    abstract:BACKGROUND:The prognostic/predictive value of aberrant MYC gene copies and protein expression is not clear in breast cancer. PATIENTS AND METHODS:Early breast cancer patients were treated with anthracycline-containing chemotherapy within 2 randomized adjuvant trials. MYC gene and centromere-8 status, as well as Myc pr...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clbc.2017.07.004

    authors: Batistatou A,Kotoula V,Bobos M,Kouvatseas G,Zagouri F,Tsolaki E,Gogas H,Koutras A,Pentheroudakis G,Timotheadou E,Pervana S,Goussia A,Petraki K,Sotiropoulou M,Koletsa T,Razis E,Kosmidis P,Aravantinos G,Papadimitriou C

    更新日期:2018-02-01 00:00:00

  • Review of Novel Sentinel Lymph Node Biopsy Techniques in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.

    abstract::Breast cancer patients who present with nodal metastasis receive neoadjuvant chemotherapy (NAC) with increasing frequency and can have complete pathologic response after treatment. In this clinical scenario, sentinel node mapping and biopsy are gaining acceptance instead of axillary dissection to avoid morbidity. Biop...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clbc.2018.01.004

    authors: Ersoy YE,Kadioglu H

    更新日期:2018-08-01 00:00:00

  • Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.

    abstract:BACKGROUND:The ExteNET trial demonstrated improved invasive disease-free survival (iDFS) with neratinib, an irreversible pan-HER tyrosine kinase inhibitor, versus placebo in patients with human epidermal growth factor receptor 2-positive (HER2+)/hormone receptor-positive (HR+) early-stage breast cancer (eBC). PATIENTS...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.09.014

    authors: Chan A,Moy B,Mansi J,Ejlertsen B,Holmes FA,Chia S,Iwata H,Gnant M,Loibl S,Barrios CH,Somali I,Smichkoska S,Martinez N,Alonso MG,Link JS,Mayer IA,Cold S,Murillo SM,Senecal F,Inoue K,Ruiz-Borrego M,Hui R,Dendulu

    更新日期:2020-10-06 00:00:00

  • N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy.

    abstract:BACKGROUND:Irinotecan has a 20% to 25% response rate (RR) in patients with previously treated metastatic breast cancer (MBC). Epidermal growth factor receptor (EGFR) is overexpressed in some MBC, especially in triple-negative breast cancer (TNBC). Cetuximab is a monoclonal antibody against EGFR with additive preclinica...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2015.08.002

    authors: Crozier JA,Advani PP,LaPlant B,Hobday T,Jaslowski AJ,Moreno-Aspitia A,Perez EA

    更新日期:2016-02-01 00:00:00

  • A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers.

    abstract:PURPOSE:The purpose of this study is to determine the response, tolerability, and long-term outcome of a neoadjuvant platinum-containing regimen for locally advanced breast cancer (LABC) and to search for a correlation between pathologic complete response (pCR) and predefined biomarkers in this cohort. PATIENTS AND ME...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2009.n.027

    authors: Yerushalmi R,Hayes MM,Gelmon KA,Chia S,Bajdik C,Norris B,Speers C,Hassell P,O'Reilly SE,Allan S,Shenkier TN

    更新日期:2009-08-01 00:00:00

  • BMI and Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer: A Study and Meta-Analysis.

    abstract:INTRODUCTION:There is only limited data from clinical practice on the relevance of body mass index (BMI) on pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC) in patients with breast cancer (BC). PATIENTS AND METHODS:The impact of BMI on pCR and survival outcome was examined in 324 patients wi...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.clbc.2016.02.018

    authors: Erbes T,Stickeler E,Rücker G,Buroh S,Asberger J,Dany N,Thornton S,Iborra S,Hirschfeld M,Gitsch G,Mayer S

    更新日期:2016-08-01 00:00:00

  • Ultrasound-Guided Vacuum-Assisted Biopsy in Small Breast: A Cost-Saving Solution.

    abstract:BACKGROUND:The study aimed to evaluate the feasibility and reliability of ultrasound-guided vacuum-assisted breast biopsy (US-VABB) for sampling of microcalcifications indicative of cancer when stereotactic vacuum-assisted breast biopsy cannot be performed because of reasons such as thin breast tissue, insufficient thi...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2018.12.002

    authors: Pistolese CA,Castrignanò A,Ricci F,Meucci R,Croce G,Mondillo M,Collura A,Perretta T,Floris R

    更新日期:2019-04-01 00:00:00

  • Bisphosphonates as anticancer therapy for early breast cancer.

    abstract::Bisphosphonates (BPs) are approved for preventing the skeletal-related events associated with malignant bone disease. Several studies indicate that they may also prevent cancer therapy-induced bone loss. Multiple preclinical and early clinical studies provide evidence of the anticancer activity of BPs, including an in...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CBC.2010.n.047

    authors: Mahtani R,Jahanzeb M

    更新日期:2010-10-01 00:00:00

  • Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.

    abstract:BACKGROUND:Although brain metastases (BM) are associated with poor prognosis, patients with human epidermal growth factor receptor 2 (HER2) overexpressing (HER2+) breast cancer (BC) with BM who are treated with anti-HER2 therapy have a relatively longer survival after BM diagnosis compared with other subtypes and HER2+...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2017.12.009

    authors: Morikawa A,Wang R,Patil S,Diab A,Yang J,Hudis CA,McArthur HL,Beal K,Seidman AD

    更新日期:2018-10-01 00:00:00

  • Impact of 21-Gene Expression Assay on Staging Estrogen Receptor-Positive HER2-Negative Breast Cancer.

    abstract:PURPOSE:The 8th edition of the American Joint Committee on Cancer (AJCC) breast cancer staging system requires histologic grade (GR), estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and stage (assessed by the tumor, node, metastasis classification system). For T1-2 N...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2018.10.005

    authors: Breaux A,Turner B,Wu X,Rai SN,Riley EC,Mandadi M,Sanders MA

    更新日期:2019-02-01 00:00:00

  • Radiotherapy in Patients 70 Years and Older With Triple-Negative Breast Cancer.

    abstract:PURPOSE:To evaluate the use of radiotherapy (RT) in older patients with triple-negative breast cancer (TNBC). PATIENTS AND METHODS:The National Cancer Data Base (NCDB) is a comprehensive national database that captures approximately 70% of newly diagnosed cancer patients in the United States. Data for patients meeting...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2016.05.011

    authors: Algan O,Zhao YD,Herman T

    更新日期:2016-08-01 00:00:00

  • Dietary Habits and Physical Activity are Associated With the Risk of Breast Cancer Among Young Iranian Women: A Case-control Study on 1010 Premenopausal Women.

    abstract:BACKGROUND:Several studies conducted in developed countries introduced diet and physical inactivity as major risk factors for several types of cancers. However, the impact of diet and physical inactivity on the risk of breast cancer (BC) is understudied, and the limited findings are controversial. In addition, no or li...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2018.10.011

    authors: Fararouei M,Iqbal A,Rezaian S,Gheibi Z,Dianatinasab A,Shakarami S,Dianatinasab M

    更新日期:2019-02-01 00:00:00

  • Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.

    abstract:BACKGROUND:Adjuvant trastuzumab improves relapse-free survival in HER2-overexpressing breast cancer but is associated with cardiac toxicity. This phase II study was undertaken to determine the neoadjuvant clinical and pathologic response rate and the acute and chronic cardiac toxicity of trastuzumab given with weekly p...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2006.n.035

    authors: Kelly H,Kimmick G,Dees EC,Collichio F,Gatti L,Sawyer L,Ivanova A,Dressler L,Graham ML,Carey LA

    更新日期:2006-08-01 00:00:00

  • Cysteine rhenium colloid: a novel radiocolloid for identifying sentinel lymph nodes in breast cancer surgery.

    abstract:BACKGROUND:Medical isotopes are required for sentinel node lymphoscintigraphy in breast cancer, but are in critical shortage. Our center uses a modification of the standard SC, called CRC, that has been shown to require less medical isotope for the same procedure. Our objective was to determine if there was a significa...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2014.07.006

    authors: Kidane B,Zabel PL,Gupta V,Whiston C,Wright F,Brackstone M

    更新日期:2015-02-01 00:00:00

  • A case of chylous fistula after axillary dissection in breast-conserving treatment for breast cancer.

    abstract::Chyle fistula is not a well-known complication of axillary dissection in patients with breast cancer. Although rare, this complication can occur as a result of anatomic variation of the thoracic duct and its venous anastomosis. Injury to the lateral terminating branches or lymphatic trunk, leading to retrograde chyle ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2006.n.030

    authors: Donkervoort SC,Roos D,Borgstein PJ

    更新日期:2006-06-01 00:00:00

  • Outcome after breast conservation treatment with radiation for women with triple-negative early-stage invasive breast carcinoma.

    abstract:BACKGROUND:Triple-negative breast carcinoma is defined by a primary tumor that is estrogen receptor negative, progesterone receptor negative, and HER2 negative. The current study was performed to determine the relationship of triple-negative tumor status to outcome after breast conservation treatment with radiation. P...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2009.n.018

    authors: Solin LJ,Hwang WT,Vapiwala N

    更新日期:2009-05-01 00:00:00

  • Spontaneous Rib Fractures After Breast Cancer Treatment Based on Bone Scans: Comparison Of Conventional Versus Hypofractionated Radiotherapy.

    abstract:BACKGROUND:Spontaneous rib fractures (SRFs) are defined as fractures without apparent blunt force trauma. This study evaluated the incidence and risk factors of SRFs after treatment of patients with breast cancer based on bone scans. In addition, we analyzed radiation-associated SRFs and identified radiotherapy (RT) fa...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.07.009

    authors: Kim DW,Kim JS,Kim K,Shin KH

    更新日期:2020-07-23 00:00:00

  • Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer.

    abstract:BACKGROUND:In first-line treatment of metastatic breast cancer, the best use of the available therapeutic agents is unclear. This study evaluated the efficacy and safety of combined therapy with bevacizumab and gemcitabine. PATIENTS:Women who were to undergo first-line treatment for locoregionally recurrent or metasta...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clbc.2012.07.004

    authors: Borson R,Harker G,Reeves J,Beck T,Hager S,Horvath W,Jones M,Tillinghast G,Arrowsmith E,Harrer G,Kudrik FJ,Malamud SC,Bromund J,Zeigler H,Tai DF,Kornberg LJ,Obasaju C,Orlando M,Yardley DA

    更新日期:2012-10-01 00:00:00

  • A method for making estimates of the benefit of the late use of letrozole in patients completing 5 years of tamoxifen.

    abstract::This article discusses the rationale for 2 methods of making estimates of the benefit of letrozole as extended adjuvant hormonal therapy after 5 years of tamoxifen. It uses information from the Overview metaanalyses to develop general rules for making estimates of remaining risk of relapse for women completing 5 years...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/cbc.2004.n.047

    authors: Ravdin PM,Davis GJ

    更新日期:2004-10-01 00:00:00

  • Rationale and design of a phase III trial of adjuvant sequential epirubicin/ cyclophosphamide and taxane versus concurrent epirubicin/taxane in operable node-positive breast cancer.

    abstract::The sequential use of a doxorubicin combination followed by paclitaxel has been reported to improve disease-free and overall survival in patients with node-positive breast cancer beyond that obtained with doxorubicin/cyclophosphamide combinations. Epirubicin is associated with less cardiotoxicity than doxorubicin and ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2000.s.010

    authors: Perez EA

    更新日期:2000-09-01 00:00:00

  • Fertility and menopausal outcomes in young breast cancer survivors.

    abstract:BACKGROUND:Following treatment for breast cancer, many young women are interested in having a child. There are few data available regarding actual fertility and menopausal outcomes in young breast cancer survivors. We evaluated these outcomes among young breast cancer survivors in collaboration with the Young Survival ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2008.n.004

    authors: Partridge AH,Gelber S,Peppercorn J,Ginsburg E,Sampson E,Rosenberg R,Przypyszny M,Winer EP

    更新日期:2008-02-01 00:00:00

  • The impact of preoperative magnetic resonance imaging on surgical treatment and outcomes for ductal carcinoma in situ.

    abstract:BACKGROUND:Although magnetic resonance imaging (MRI) is a useful imaging modality for invasive cancer, its role in preoperative surgical planning for ductal carcinoma in situ (DCIS) has not been established. We sought to determine whether preoperative MRI affects surgical treatment and outcomes in women with pure DCIS....

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2011.n.006

    authors: Itakura K,Lessing J,Sakata T,Heinzerling A,Vriens E,Wisner D,Alvarado M,Esserman L,Ewing C,Hylton N,Hwang ES

    更新日期:2011-03-01 00:00:00

  • A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer.

    abstract:BACKGROUND:The purpose of this study was to investigate whether combining pembrolizumab with palliative radiation therapy (RT) improves outcomes in patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC). PATIENTS AND METHODS:Eligible patients had HR+/human epidermal growth factor receptor 2-negat...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.01.012

    authors: Barroso-Sousa R,Krop IE,Trippa L,Tan-Wasielewski Z,Li T,Osmani W,Andrews C,Dillon D,Richardson ET 3rd,Pastorello RG,Winer EP,Mittendorf EA,Bellon JR,Schoenfeld JD,Tolaney SM

    更新日期:2020-06-01 00:00:00

  • Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial.

    abstract::Over the past 30 years there has been an increased use of neoadjuvant (or primary) chemotherapy for treating patients with breast cancer. However, while it is clear that chemotherapy given in the adjuvant setting after surgery does prolong patients' overall and disease-free survival, the evidence that chemotherapy in ...

    journal_title:Clinical breast cancer

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.3816/cbc.2002.s.015

    authors: Heys SD,Hutcheon AW,Sarkar TK,Ogston KN,Miller ID,Payne S,Smith I,Walker LG,Eremin O,Aberdeen Breast Group.

    更新日期:2002-10-01 00:00:00

  • The impact of re-excision and residual disease on local recurrence after breast conservation treatment for patients with early stage breast cancer.

    abstract:UNLABELLED:The current study examined the impact of re-excision and residual disease on local recurrence after breast conservation treatment for patients with negative margins. Patients with residual disease on re-excision had a higher local recurrence rate than other patients. However, with reasonably low local recurr...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2011.08.003

    authors: Ali AN,Vapiwala N,Guo M,Hwang WT,Harris EE,Solin LJ

    更新日期:2011-12-01 00:00:00

  • Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG).

    abstract::In addition to classical clinicopathologic factors, such as hormone receptor positivity, human epidermal growth factor receptor 2 (HER2) status, and tumor size, grade, and lymph node status, a number of commercially available genomic tests may be used to help inform treatment decisions for early breast cancer patients...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clbc.2020.01.001

    authors: Kittaneh M,Badve S,Caldera H,Coleman R,Goetz MP,Mahtani R,Mamounas E,Kalinsky K,Lower E,Pegram M,Press MF,Rugo HS,Schwartzberg L,Traina T,Vogel C

    更新日期:2020-06-01 00:00:00

  • The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.

    abstract::Tamoxifen reduced the risk of invasive breast cancer by 49% among women at increased risk for breast cancer in the Breast Cancer Prevention Trial P-1, and raloxifene reduced breast cancer incidence by more than 70% in the Multiple Outcomes of Raloxifene Evaluation osteoporosis trial. These findings led the National Su...

    journal_title:Clinical breast cancer

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.3816/CBC.2002.n.020

    authors: Vogel VG,Costantino JP,Wickerham DL,Cronin WM,Wolmark N

    更新日期:2002-06-01 00:00:00